Re-treatment with PARPi in patients with recurrent epithelial ovarian cancer: A single institutional experience

INTRODUCTION: We aimed to evaluate real-life experiences with the re-challenge of poly(ADP-Ribose)Polymerase (PARP) inhibitors (PARPi) after a prior PARPi therapy in patients with recurrent EOC. METHODS: A retrospective descriptive study was conducted at a tertiary care center of excellence for ovar...

Descripción completa

Detalles Bibliográficos
Autores principales: Moubarak, Malak, Harter, Philipp, Ataseven, Beyhan, Traut, Alexander, Welz, Julia, Baert, Thais, Heitz, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8829558/
https://www.ncbi.nlm.nih.gov/pubmed/35169607
http://dx.doi.org/10.1016/j.gore.2022.100939

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8829558/
https://www.ncbi.nlm.nih.gov/pubmed/35169607
http://dx.doi.org/10.1016/j.gore.2022.100939

Ejemplares similares